Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.39 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.39 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.39 |
| ▸ | TK2 | O00142 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2972166 | 1.00 | P2RY6 (0.44) | P2RY6ALDH1A1HTTP2RY14NT5E | |
| SCHEMBL3287903 | 0.92 | P2RY6 (0.43) | P2RY6ALDH1A1HTTP2RY14NT5E | |
| SCHEMBL19407978 | 0.92 | P2RY6 (0.43) | P2RY6ALDH1A1HTTP2RY14NT5E | |
| SCHEMBL14363434 | 0.92 | P2RY6 (0.43) | P2RY6ALDH1A1HTTP2RY14NT5E | |
| SCHEMBL19407903 | 0.91 | POLB (0.42) | P2RY6ALDH1A1HTTP2RY14NT5E | |
| SCHEMBL3287912 | 0.90 | P2RY6 (0.41) | P2RY6ALDH1A1HTTP2RY14NT5E | |
| SCHEMBL2985322 | 0.90 | P2RY6 (0.51) | P2RY6ALDH1A1HTTP2RY14NT5E | |
| SCHEMBL2985316 | 0.90 | P2RY6 (0.51) | P2RY6ALDH1A1HTTP2RY14NT5E | |
| SCHEMBL7252603 | 0.88 | P2RY6 (0.41) | P2RY6ALDH1A1HTTP2RY14NT5E | |
| SCHEMBL13205002 | 0.88 | P2RY6 (0.44) | P2RY6ALDH1A1HTTP2RY14NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401852-B1 | METHODS FOR PREPARING OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHOROTHIOATE LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2013-09-11 | — | — | EP | disclosed |
| US-7772387-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2010-08-10 | — | — | US | disclosed |
| US-7723511-B2 | Synthesis of sulfurized oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579451-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080293929-A1 | SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-7378516-B2 | Synthesis of sulfurized oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1828215-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | Alnylam Pharmaceuticals Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-7227015-B2 | Synthesis of sulfurized oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| WO-2006093526-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060041115-A1 | Methods for preparing oligonucleotides having chiral phosphorothioate linkages | ISIS PHARMACEUTICALS, INC. | 2006-02-23 | — | — | US | disclosed |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| US-20050165226-A1 | Synthesis of sulfurized oligonucleotides | ISIS PHARMACEUTICALS INC. | 2005-07-28 | — | — | US | disclosed |
| US-20030212267-A1 | Synthesis of sulfurized oligonucleotides | IONIS PHARMACEUTICALS, INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030069410-A1 | Methods for preparing oligonucleotides having chiral phosphorothioate linkages | ISIS PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | disclosed |
| EP-1246833-A4 | IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-1246833-A1 | IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001051502-A1 | IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| US-6242591-B1 | Synthesis of sulfurized 2'-substituted oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2001-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041115-A1 | Methods for preparing oligonucleotides having chiral phosphorothioate linkages | RNGTT, NUDT1, NSUN2 | P2RY6 1017/4885ALDH1A1 3923/4885HTT 2220/4885 |
| US-20030069410-A1 | Methods for preparing oligonucleotides having chiral phosphorothioate linkages | RNGTT, TYMP, POLN | P2RY6 841/4885ALDH1A1 3152/4885HTT 1251/4885 |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | NT5C3B, DERA, DUT | P2RY6 121/4885ALDH1A1 1623/4885HTT 1094/4885 |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | NT5C3B, DERA, DUT | P2RY6 121/4885ALDH1A1 1623/4885HTT 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.